Zero Ischemia LRATE May Produce Superior Outcomes in cT1a Renal Tumors
Zero ischemia laparoscopic radiofrequency ablation assisted tumor enucleation (LRATE) allows for tumor excision.
Zero ischemia laparoscopic radiofrequency ablation assisted tumor enucleation (LRATE) allows for tumor excision with superior renal function preservation compared with laparoscopic partial nephrectomy (LPN), a study has found.1
In this prospective randomized controlled trial, researchers sought to evaluate functional outcome, safety, and efficacy of zero ischemia, LRATE compared with conventional LPN.
A total of 89 patients with cT1a renal tumor scheduled for laparoscopic nephron-sparing surgery were enrolled: 44 patients were randomized to the LRATE group and 45 to the LPN group.
The study's primary endpoint was change in glomerular filtration rate (GFR) of the affected kidney by renal scintigraphy at 12 months. Secondary endpoints included changes of estimated GFR, estimated blood loss, operative time, hospital stay, postoperative complications, and oncologic outcomes.
RELATED: Greater Renal Tumor Enhancement Is a Risk Factor for Radiofrequency Ablation
Results showed that patients in the LRATE group had less decrease in GFR of the affected kidney at 3 months (10.2% vs 20.5%; P = .001) and at 12 months (7.6% vs 16.2%; P = .002). Those in the LRATE group also had shorter operative time, less estimated blood loss, and shorter hospital stays. The rate of postoperative complications was similar between groups.
- Huang J, Zhang J, Wang Y, et al. Comparing zero ischemia laparoscopic radiofrequency ablation assisted tumor enucleation and laparoscopic partial nephrectomy for clinical T1a renal tumor: a randomized clinical trial [published online ahead of print February 21, 2016]. J Urol. doi: 10.1016/j.juro.2015.12.115.